Ligand identification for G-protein-coupled receptors: a lead generation perspective.

This review addresses strategies for the generation of ligands for G-protein-coupled receptors outside classical high-throughput screening and literature based approaches. These range from the chemical intuition-based strategies of endogenous ligand elaboration and privileged structure decoration to the in silico approaches of virtual screening and de novo design. Examples are cited where supporting pharmacological data has been presented.

[1]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[2]  Gerhard Klebe,et al.  Ligand-supported homology modeling of g-protein-coupled receptor sites: models sufficient for successful virtual screening. , 2004, Angewandte Chemie.

[3]  C. Derian,et al.  Design and evaluation of potent peptide‐mimetic PAR1 antagonists , 2003 .

[4]  Philip M. Dean,et al.  slate: A method for the superposition of flexible ligands , 2001, J. Comput. Aided Mol. Des..

[5]  T. Inoue,et al.  2-Alkynyl-8-aryladenines possessing an amide moiety: their synthesis and structure-activity relationships of effects on hepatic glucose production induced via agonism of the A(2B) adenosine receptor. , 2001, Bioorganic & medicinal chemistry.

[6]  Frank Diehl,et al.  Identification of the Binding Site for a Novel Class of CCR2b Chemokine Receptor Antagonists , 2000, The Journal of Biological Chemistry.

[7]  K. Valenzano,et al.  Design and parallel synthesis of piperidine libraries targeting the nociceptin (N/OFQ) receptor. , 2003, Bioorganic & medicinal chemistry letters.

[8]  J. Drews.  Drug discovery: a historical perspective. , 2000, Science.

[9]  R G Smith,et al.  Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. , 1998, Science.

[10]  Didier Rognan,et al.  Protein‐based virtual screening of chemical databases. II. Are homology models of g‐protein coupled receptors suitable targets? , 2002, Proteins.

[11]  H. Stark.  Recent advances in histamine H3/H4 receptor ligands , 2003 .

[13]  G. Schneider,et al.  Integrating Virtual Screening Methods to the Quest for Novel Membrane Protein Ligands , 2001 .

[14]  D. Denis,et al.  Structure–Activity Relationship of Biaryl Acylsulfonamide Analogues on the Human EP3 Prostanoid Receptor , 2002 .

[15]  Gisbert Schneider,et al.  Ligand-based combinatorial design of selective purinergic receptor (A2A) antagonists using self-organizing maps. , 2003, Journal of combinatorial chemistry.

[16]  D. Hoyer,et al.  Design and synthesis of gamma-dipeptide derivatives with submicromolar affinities for human somatostatin receptors. , 2003, Angewandte Chemie.

[17]  Gerhard Hessler,et al.  Drug Design Strategies for Targeting G‐Protein‐Coupled Receptors , 2002, Chembiochem : a European journal of chemical biology.

[18]  Douglas A. Horton,et al.  The combinatorial synthesis of bicyclic privileged structures or privileged substructures. , 2003, Chemical reviews.

[19]  V. Tschinke,et al.  Biphenyl derivatives as novel dual NK(1)/NK(2)-receptor antagonists. , 2002, Bioorganic & medicinal chemistry letters.

[20]  Y. Cho,et al.  Design and synthesis of a piperazinylalkylisoxazole library for subtype selective dopamine receptor ligands. , 2002, Bioorganic & medicinal chemistry letters.

[21]  G. Adam,et al.  Novel hexahydrospiro[piperidine-4,1'-pyrrolo[3,4-c]pyrroles]: highly selective small-molecule nociceptin/orphanin FQ receptor agonists. , 2003, Journal of medicinal chemistry.

[22]  Yong‐Chul Kim,et al.  Application of a novel design paradigm to generate general nonpeptide combinatorial scaffolds mimicking beta turns: synthesis of ligands for somatostatin receptors. , 2003, Bioorganic & medicinal chemistry.

[23]  D. Kostrewa,et al.  Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. , 2000, Journal of medicinal chemistry.

[24]  L. Santana,et al.  New arylpiperazine derivatives with high affinity for alpha1A, D2 and 5-HT2A receptors. , 2003, Bioorganic & medicinal chemistry letters.

[25]  P. Hajduk,et al.  Privileged molecules for protein binding identified from NMR-based screening. , 2000, Journal of medicinal chemistry.

[26]  Arthur A. Patchett,et al.  Chapter 26. Privileged structures — An update , 2000 .

[27]  P. Krogsgaard‐Larsen,et al.  Ligands for glutamate receptors: design and therapeutic prospects. , 2000, Journal of medicinal chemistry.

[28]  S. Shuto,et al.  Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure. , 2003, Journal of medicinal chemistry.

[29]  F. Makovec,et al.  Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives. , 1992, Journal of medicinal chemistry.

[30]  Kirsch,et al.  Virtual Screening for Bioactive Molecules by Evolutionary De Novo Design Special thanks to Neil R. Taylor for his help in preparation of the manuscript. , 2000, Angewandte Chemie.

[31]  A. Good,et al.  3-D pharmacophores in drug discovery. , 2001, Current pharmaceutical design.

[32]  T D Perkins,et al.  Development of a pharmacophore model for histamine H3 receptor antagonists, using the newly developed molecular modeling program SLATE. , 2001, Journal of medicinal chemistry.

[33]  D. Seebach,et al.  Design, Synthesis, NMR-Solution and X-Ray Crystal Structure ofN-Acyl-γ-dipeptide Amides That Form aβII′-Type Turn , 2001 .

[34]  K. Chapman,et al.  Combinatorial synthesis of 3-(amidoalkyl) and 3-(aminoalkyl)-2-arylindole derivatives: discovery of potent ligands for a variety of G-protein coupled receptors. , 2002, Bioorganic & medicinal chemistry letters.

[35]  R. Osman,et al.  Minireview: Insights into G Protein-Coupled Receptor Function Using Molecular Models* * The work from our laboratories was supported by USPHS Grant DK-43036. , 2001, Endocrinology.

[36]  D. Poyner,et al.  Combinatorial solid phase synthesis of multiply substituted 1,4-benzodiazepines and affinity studies on the CCK2 receptor (part 1). , 2002, Drug design and discovery.

[37]  K. Bleicher,et al.  Parallel solution- and solid-phase synthesis of spiropyrrolo-pyrroles as novel neurokinin receptor ligands. , 2002, Bioorganic & medicinal chemistry letters.

[38]  E. Jacoby.  A Novel Chemogenomics Knowledge-Based Ligand Design Strategy—Application to G Protein-Coupled Receptors , 2001 .

[39]  Jürgen Bajorath,et al.  Integration of virtual and high-throughput screening , 2002, Nature Reviews Drug Discovery.

[40]  D. Denis,et al.  Structure-activity relationship of cinnamic acylsulfonamide analogues on the human EP3 prostanoid receptor. , 2001, Bioorganic & medicinal chemistry.

[41]  A. Macleod,et al.  Serine derived NK1 antagonists. 1: The effect of modifications to the serine substituents. , 1998, Bioorganic & medicinal chemistry letters.

[42]  K. Inoguchi,et al.  Rational design, discovery, and synthesis of a novel series of potent growth hormone secretagogues. , 2001, Journal of medicinal chemistry.

[43]  P. Ornstein,et al.  Synthesis and structure-activity relationship studies of novel 2-diarylethyl substituted (2-carboxycycloprop-1-yl)glycines as high-affinity group II metabotropic glutamate receptor ligands. , 2003, Bioorganic & medicinal chemistry.

[44]  Mark A. Murcko,et al.  Virtual screening : an overview , 1998 .

[45]  A. Souers,et al.  Identification of a Potent Heterocyclic Ligand To Somatostatin Receptor Subtype 5 by the Synthesis and Screening of β-Turn Mimetic Libraries , 1999 .

[46]  R. Osman,et al.  Role of the extracellular loops of the thyrotropin-releasing hormone receptor: evidence for an initial interaction with thyrotropin-releasing hormone. , 1997, Biochemistry.

[47]  L. V. D. van der Ploeg,et al.  Spiro(indoline-3,4'-piperidine) growth hormone secretagogues as ghrelin mimetics. , 2001, Bioorganic & medicinal chemistry letters.

[48]  R. Glennon,et al.  γ-carbolines : Binding at 5-HT5A serotonin receptors , 2003 .

[49]  A. Patchett,et al.  Spiro[1H-indene-1,4'-piperidine] derivatives as potent and selective non-peptide human somatostatin receptor subtype 2 (sst2) agonists. , 1998, Journal of medicinal chemistry.

[50]  T. Klabunde,et al.  Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. , 2002, Journal of medicinal chemistry.

[51]  A. IJzerman,et al.  2,8-Disubstituted adenosine derivatives as partial agonists for the adenosine A2A receptor. , 2003, Bioorganic & medicinal chemistry.

[52]  Parallel solution- and solid-phase synthesis of spirohydantoin derivatives as neurokinin-1 receptor ligands. , 2002, Bioorganic & medicinal chemistry letters.

[53]  S. Moro,et al.  Role of the extracellular loops of G protein-coupled receptors in ligand recognition: a molecular modeling study of the human P2Y1 receptor. , 1999, Biochemistry.

[54]  C. Rizzo,et al.  Coordination of Histamine H3 Receptor Antagonists with Human Adrenal Cytochrome P450 Enzymes , 2002, Pharmacology.

[55]  J. Pin,et al.  The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. , 2002, Current drug targets. CNS and neurological disorders.

[56]  P. Plas,et al.  Identification of potent non-peptide somatostatin antagonists with sst(3) selectivity. , 2001, Journal of medicinal chemistry.

[57]  I. D. de Esch,et al.  A Qualitative Model for the Histamine H3 Receptor Explaining Agonistic and Antagonistic Activity Simultaneously , 2000, Archiv der Pharmazie.

[58]  G. Schneider,et al.  Virtual Screening for Bioactive Molecules , 2000 .

[59]  B. E. Evans,et al.  Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of Medicinal Chemistry.

[60]  Edgar Jacoby,et al.  Biphenyls as potential mimetics of protein α-helix , 2002 .

[61]  Philip M Dean,et al.  Scaffold hopping in de novo design. Ligand generation in the absence of receptor information. , 2004, Journal of medicinal chemistry.

[62]  Xueliang Fang,et al.  Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. , 2003, Journal of medicinal chemistry.

[63]  A. Stevens,et al.  Computational design strategies for combinatorial libraries. , 2003, Current opinion in chemical biology.